Compare ALEMBIC with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs WOCKHARDT - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC WOCKHARDT ALEMBIC/
WOCKHARDT
 
P/E (TTM) x 57.8 -89.5 - View Chart
P/BV x 5.0 2.0 251.3% View Chart
Dividend Yield % 0.2 0.0 10,522.0%  

Financials

 ALEMBIC   WOCKHARDT
EQUITY SHARE DATA
    ALEMBIC
Mar-18
WOCKHARDT
Mar-18
ALEMBIC/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs721,012 7.1%   
Low Rs34532 6.4%   
Sales per share (Unadj.) Rs4.7355.9 1.3%  
Earnings per share (Unadj.) Rs6.1-60.3 -10.1%  
Cash flow per share (Unadj.) Rs6.2-46.8 -13.4%  
Dividends per share (Unadj.) Rs0.200.01 2,000.0%  
Dividend yield (eoy) %0.40 29,150.1%  
Book value per share (Unadj.) Rs40.7257.8 15.8%  
Shares outstanding (eoy) m267.03110.63 241.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.32.2 519.4%   
Avg P/E ratio x8.7-12.8 -67.8%  
P/CF ratio (eoy) x8.5-16.5 -51.4%  
Price / Book Value ratio x1.33.0 43.5%  
Dividend payout %3.30 -19,751.4%   
Avg Mkt Cap Rs m14,13985,379 16.6%   
No. of employees `000NA6.3 0.0%   
Total wages/salary Rs m2079,371 2.2%   
Avg. sales/employee Rs ThNM6,295.0-  
Avg. wages/employee Rs ThNM1,498.3-  
Avg. net profit/employee Rs ThNM-1,066.3-  
INCOME DATA
Net Sales Rs m1,25539,369 3.2%  
Other income Rs m3701,202 30.8%   
Total revenues Rs m1,62540,571 4.0%   
Gross profit Rs m11118 607.1%  
Depreciation Rs m381,495 2.5%   
Interest Rs m22,555 0.1%   
Profit before tax Rs m442-2,830 -15.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m24257 9.3%   
Profit after tax Rs m1,630-6,669 -24.4%  
Gross profit margin %8.90 19,041.6%  
Effective tax rate %5.4-9.1 -59.7%   
Net profit margin %129.8-16.9 -766.6%  
BALANCE SHEET DATA
Current assets Rs m1,86733,796 5.5%   
Current liabilities Rs m59126,917 2.2%   
Net working cap to sales %101.617.5 581.8%  
Current ratio x3.21.3 251.5%  
Inventory Days Days9479 118.8%  
Debtors Days Days7489 82.4%  
Net fixed assets Rs m1,79139,664 4.5%   
Share capital Rs m534553 96.5%   
"Free" reserves Rs m10,32427,968 36.9%   
Net worth Rs m10,85828,522 38.1%   
Long term debt Rs m4121,731 0.2%   
Total assets Rs m11,59181,620 14.2%  
Interest coverage x260.9-0.1 -242,638.6%   
Debt to equity ratio x00.8 0.5%  
Sales to assets ratio x0.10.5 22.5%   
Return on assets %14.1-5.0 -279.3%  
Return on equity %15.0-23.4 -64.2%  
Return on capital %15.2-7.7 -197.9%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m199,807 0.2%   
Fx outflow Rs m2641,789 14.8%   
Net fx Rs m-2448,019 -3.0%   
CASH FLOW
From Operations Rs m236684 34.5%  
From Investments Rs m-2246,302 -3.6%  
From Financial Activity Rs m-27-7,695 0.3%  
Net Cashflow Rs m-15-664 2.2%  

Share Holding

Indian Promoters % 64.0 74.5 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 2.3 8.7%  
FIIs % 9.7 7.7 126.0%  
ADR/GDR % 0.0 0.1 -  
Free float % 26.1 15.4 169.5%  
Shareholders   54,701 67,757 80.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  VENUS REMEDIES  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower; Dow Futures Down by 101 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading up by 357 points, up 0.7% at 49,267 levels.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Jan 22, 2021 03:36 PM

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS